Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | PRESIDENT & CSO | February 19, 2025 | February 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date February 19, 2025 · Filed February 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 579,388 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Sale · Disposed 1,326 · Balance 579,388 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2025 Filed Feb 21, 2025 16:23 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,326 | $1.15 | $1,525.17 |
DisclosureSEC source: 0001415889-25-005069 · form4-02212025_090208.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · PRESIDENT & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 579,388 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 18:09 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-25-001961 · form4-01232025_110133.xml · derivative · entry 1 Pons Jaume · CIK 0001816977 · PRESIDENT & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on February 21, 2025. Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 16:43 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 10,796 | $1.58 | $17,059.84 |
DisclosureSEC source: 0001415889-25-000123 · form4-01022025_090125.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · PRESIDENT & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 580,714 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 14, 2024 Filed Aug 16, 2024 17:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,937 | $2.58 | $4,997.46 |
DisclosureSEC source: 0001415889-24-021474 · form4-08162024_090846.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · PRESIDENT & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 591,510 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 16:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001415889-24-019546 · form4-07152024_080721.xml · derivative · entry 3 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,433 Underlying: Common Stock · 20,000 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 16:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 20,000 | $7.90 | $158,076.00 |
DisclosureSEC source: 0001415889-24-019546 · form4-07152024_080721.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 593,447 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to 7.905, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 16:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 20,000 | $0.99 | $19,800.00 |
DisclosureSEC source: 0001415889-24-019546 · form4-07152024_080721.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 613,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 17:00 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 10,758 | $5.82 | $62,598.65 |
DisclosureSEC source: 0001415889-24-019221 · form4-07032024_090724.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 593,447 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.78 to $5.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 16:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001415889-24-015737 · form4-06062024_080618.xml · derivative · entry 3 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,433 Underlying: Common Stock · 20,000 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 16:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 20,000 | $8.43 | $168,652.00 |
DisclosureSEC source: 0001415889-24-015737 · form4-06062024_080618.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 604,205 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.17 to $8.87, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 16:06 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 20,000 | $0.99 | $19,800.00 |
DisclosureSEC source: 0001415889-24-015737 · form4-06062024_080618.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 624,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2024 Filed May 8, 2024 17:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001415889-24-012637 · form4-05082024_090502.xml · derivative · entry 3 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,433 Underlying: Common Stock · 20,000 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| May 06, 2024 Filed May 8, 2024 17:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 20,000 | $15.92 | $318,334.00 |
DisclosureSEC source: 0001415889-24-012637 · form4-05082024_090502.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 604,205 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.55 to $16.3942, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2024 Filed May 8, 2024 17:31 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 20,000 | $0.99 | $19,800.00 |
DisclosureSEC source: 0001415889-24-012637 · form4-05082024_090502.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 624,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 16:49 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 25,846 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001415889-24-011128 · form4-04182024_080417.xml · derivative · entry 3 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,433 Underlying: Common Stock · 25,846 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 16:49 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 50,000 | $14.20 | $710,195.00 |
DisclosureSEC source: 0001415889-24-011128 · form4-04182024_080417.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 604,205 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.47, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 16:49 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 25,846 | $0.99 | $25,587.54 |
DisclosureSEC source: 0001415889-24-011128 · form4-04182024_080417.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 654,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 17:37 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 20,000 | $11.15 | $223,036.00 |
DisclosureSEC source: 0001415889-24-010443 · form4-04052024_090425.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 628,359 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 6, 2023. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.86 to $11.275, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 18:09 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $15.84 | $0.00 |
DisclosureSEC source: 0001415889-24-004218 · form4-02162024_110225.xml · derivative · entry 2 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2034-02-13 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on March 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 18:09 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004218 · form4-02162024_110225.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · PRESIDENT & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 648,359 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on August 14, 2024. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 16:17 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 7,179 | $15.04 | $107,972.16 |
DisclosureSEC source: 0001209191-24-000359 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 618,359 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:11 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 282,000 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0001209191-23-043514 · doc4.xml · derivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,000 Underlying: Common Stock · 282,000 shares Expires 2033-07-24 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 3, 2023. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:11 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 89,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043514 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,538 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on December 28, 2023. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 17:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 3,208 | $7.34 | $23,546.72 |
DisclosureSEC source: 0001209191-23-041197 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 536,538 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 20:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 3,232 | $11.07 | $35,778.56 |
DisclosureSEC source: 0001209191-23-000472 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,746 F1 · kind: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.07 to $11.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 17:55 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 244,000 | $0.00 Strike: $11.47 | $0.00 |
DisclosureSEC source: 0001209191-22-045054 · doc4.xml · derivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,000 Underlying: Common Stock · 244,000 shares Expires 2032-08-04 F2 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 1, 2022. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 17:55 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantCommon Stock | 74,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045054 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 542,978 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in eight equal semiannual installments beginning on December 28, 2022. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 08:27 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,254 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001209191-22-007348 · doc4.xml · derivative · entry 4 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,128 Underlying: Common Stock · 12,254 shares Expires 2029-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on June 16, 2019. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 08:27 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,900 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-22-007348 · doc4.xml · derivative · entry 3 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,279 Underlying: Common Stock · 11,900 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 08:27 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 12,254 | $1.91 | $23,405.14 |
DisclosureSEC source: 0001209191-22-007348 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 08:27 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 11,900 | $0.99 | $11,781.00 |
DisclosureSEC source: 0001209191-22-007348 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 226 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 19:10 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,229 | $55.12 | $122,866.49 |
DisclosureSEC source: 0001209191-21-061198 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,598 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.74 to $55.66, inclusive. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 19:10 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 14,471 | $54.17 | $783,847.76 |
DisclosureSEC source: 0001209191-21-061198 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,827 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.70 to $54.65,inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 19:09 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,229 | $55.12 | $122,866.49 |
DisclosureSEC source: 0001209191-21-061195 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,598 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.74 to $55.66, inclusive. Read SEC document |
| October 19, 2021 Filed Oct 20, 2021 19:09 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 14,471 | $54.17 | $783,847.76 |
DisclosureSEC source: 0001209191-21-061195 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,827 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.70 to $54.65,inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 16:17 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 235 | $76.46 | $17,968.71 |
DisclosureSEC source: 0001209191-21-057033 · doc4.xml · nonDerivative · entry 4 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,298 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.14 to $76.60, inclusive. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 16:17 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,714 | $75.46 | $129,336.04 |
DisclosureSEC source: 0001209191-21-057033 · doc4.xml · nonDerivative · entry 3 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,533 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.13 to $76.12, inclusive. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 16:17 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 10,322 | $74.42 | $768,153.95 |
DisclosureSEC source: 0001209191-21-057033 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,247 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.11 to $75.105, inclusive. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 16:17 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 4,429 | $73.78 | $326,753.90 |
DisclosureSEC source: 0001209191-21-057033 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,569 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.11 to $74.105, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 617 | $66.24 | $40,871.50 |
DisclosureSEC source: 0001209191-21-052864 · doc4.xml · nonDerivative · entry 7 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 477,998 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.86 to $66.845, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,373 | $65.60 | $90,073.74 |
DisclosureSEC source: 0001209191-21-052864 · doc4.xml · nonDerivative · entry 6 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,615 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.87 to $65.85, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 556 | $64.22 | $35,706.38 |
DisclosureSEC source: 0001209191-21-052864 · doc4.xml · nonDerivative · entry 5 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479,988 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.63 to $64.625, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,190 | $62.84 | $74,784.48 |
DisclosureSEC source: 0001209191-21-052864 · doc4.xml · nonDerivative · entry 4 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,544 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.46 to $63.34, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,324 | $61.91 | $81,971.75 |
DisclosureSEC source: 0001209191-21-052864 · doc4.xml · nonDerivative · entry 3 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 481,734 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.45 to $62.44, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 4,007 | $60.78 | $243,532.64 |
DisclosureSEC source: 0001209191-21-052864 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,058 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.44 to $61.43, inclusive. Read SEC document |
| August 19, 2021 Filed Aug 20, 2021 20:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 7,633 | $59.79 | $456,399.97 |
DisclosureSEC source: 0001209191-21-052864 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,065 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.44 to $60.435, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) through (9) to this Form 4. F3 · balance_after: Includes 152 shares acquired under the Issuer's employee stock purchase plan on June 30, 2021. Read SEC document |
| July 30, 2021 Filed Aug 3, 2021 17:04 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $58.56 | $0.00 |
DisclosureSEC source: 0001209191-21-049385 · doc4.xml · derivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2031-07-29 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 30, 2021. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 16:12 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 5,900 | $55.08 | $324,983.80 |
DisclosureSEC source: 0001209191-21-047365 · doc4.xml · nonDerivative · entry 3 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,546 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.03 to $55.23, inclusive. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 16:12 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 9,500 | $54.37 | $516,553.00 |
DisclosureSEC source: 0001209191-21-047365 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,446 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.00 to $54.95, inclusive. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 16:12 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,300 | $53.62 | $69,708.21 |
DisclosureSEC source: 0001209191-21-047365 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,946 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.